Stocktoria
Cryoport, Inc. CYRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-07-24
Cryoport, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 47.1% | 44.4% | 44.7% | 43.8% | 43.4% |
| Operating margin | -20.9% | -77.6% | -59.6% | -13.4% | -8.0% |
| Net margin | 44.4% | -73.2% | -59.0% | -15.7% | -123.8% |
| FCF margin | -14.2% | -21.4% | -23.4% | -10.1% | -7.1% |
| Return on assets | 10.2% | -16.3% | -10.4% | -3.6% | -24.8% |
| Return on equity | 15.6% | -28.6% | -20.4% | -6.7% | -42.9% |
| Current ratio | 2.17 | 5.29 | 11.73 | 14.79 | 16.26 |
| Revenue growth | 12.4% | -7.1% | -28.9% | 6.6% | 182.9% |
Source: SEC EDGAR filings · CIK 0001124524 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.